PatentVest released a report highlighting a $19 billion investment surge in amylin-based drugs, now central to obesity treatment strategies. Nearly 40 programs are in development, including a GLP-1/amylin combo nearing FDA review, showing potential for over 20% weight loss. The report emphasizes the growing importance of patent strategy alongside clinical efficacy in this competitive field. Upcoming clinical and regulatory milestones in the next 18 months will further shape the market landscape.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
